Search
Deferiprone
go.drugbank.com/drugs/DB08826ApprovedInvestigationalFDA approved on October 14, 2011. … Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs.
Synonyms: 3-Hydroxy-1,2-dimethyl-4(1H)-pyridoneCategories: Heterocyclic Compounds, 1-Ring, Compounds used in a research, industrial, or household settingArsenic trioxide
go.drugbank.com/drugs/DB01169ApprovedInvestigationalArsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. … In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects.
Products: LEUSENOX 10 MG/10 ML IV INFÜZYON IÇIN KONSANTRE ÇÖZELTI IÇEREN AMPUL, 10 ADET, LEUSENOX 10 MG/10 ML IV INFÜZYON IÇIN KONSANTRE ÇÖZELTI IÇEREN AMPUL, 1 ADETEdoxaban
go.drugbank.com/drugs/DB09075ApprovedInvestigational(PE) following 5-10 days of initial therapy with a parenteral anticoagulant. … be on lifelong therapy.
Categories: Heterocyclic Compounds, 1-RingProducts: LIXIANA 15 MG FILM KAPLI TABLET ,10 TABLET, LIXIANA 30 MGAtezolizumab
go.drugbank.com/drugs/DB11595ApprovedInvestigational[L7489] Atezolizumab was granted FDA approval on 18 October 2016. … Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: TECENTRIQ CONCENTRATE FOR SOLUTION FOR INFUSION 1200 MG/ 20 ML, TECENTRIQ 1200 MG / 20 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADETTirzepatide
go.drugbank.com/drugs/DB15171ApprovedInvestigational[A246265] Tirzepatide was approved by the FDA on May 13, 2022, under the brand name MOUNJARO by the FDA for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor … [L48766] On September 15, 2022, tirzepatide was also approved by the European Commission.[L44386]. On November 02, 2023, tirzepatide was also approved by the Health Canada [L52800]
Categories: GLP-1 Agonists, Receptors, G-Protein-CoupledProducts: Mounjaro 10 mg solution for injection in vial, Mounjaro 10 mg solution for injection in pre-filled penZolpidem
go.drugbank.com/drugs/DB00425ApprovedInvestigationalZolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. … In addition, zolpidem improves sleep quality in patients suffering from chronic insomnia and can show mild muscle relaxant properties [L5584].
Synonyms: N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamideCategories: Heterocyclic Compounds, 1-RingCefazolin
go.drugbank.com/drugs/DB01327ApprovedInvestigationalA semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.
Synonyms: (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acidMixtures: CEFAMEZIN 250 MG IM ENJEKTABL TOZ İÇEREN FLAKON, 1 ADET, CEFAMEZIN 500 MG IM ENJEKTABL TOZ İÇEREN FLAKON, 1 ADETEmpagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigationalEmpagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. … [A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus.
Mixtures: GLYXAMBI® 10 MG/ 5 MG, GLYXAMBI® 10 MG/ 5 MGCategories: Drugs Used in Diabetes, Sodium-Glucose Transporter 2 InhibitorsOcrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigationalPrimary progressive multiple sclerosis (PPMS) accounts for 10-15% of the overall population of patients with MS, and leads to the gradual worsening of neurologic disability from symptom onset, often without … In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a].
Products: OCREVUS 300 MG/10 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 2 ADET, OCREVUS 300 MG/10 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADETNiacin
go.drugbank.com/drugs/DB00627ApprovedInvestigationalNutraceuticalNiacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.
Synonyms: m-pyridinecarboxylic acidMixtures: Niacin 500 Mg and Inositol, 50 Plus